Fibrolamellar Carcinoma clinical trials at University of California Health
2 research studies open to eligible people
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
open to eligible people ages 0-30
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Experimental Cisplatin and Combination Chemotherapy in Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
open to eligible people ages up to 30 years
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.
at UC Davis UCLA UCSF
Our lead scientists for Fibrolamellar Carcinoma research studies include Noah C. Federman Arun A. Rangaswami Carla B. Golden Marcio H. Malogolowkin.